Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report) Director Jason Aryeh sold 3,000 shares of the company’s stock in a transaction dated Tuesday, November 10th. The shares were sold at an average price of $320.05, for a total transaction of $960,150.00. Following the transaction, the director owned 105,476 shares in the company, valued at $33,757,593.80. The trade was a 2.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Jason Aryeh also recently made the following trade(s):
- On Wednesday, November 4th, Jason Aryeh sold 282 shares of Ligand Pharmaceuticals stock. The stock was sold at an average price of $319.99, for a total transaction of $90,237.18.
- On Monday, November 2nd, Jason Aryeh sold 700 shares of Ligand Pharmaceuticals stock. The stock was sold at an average price of $320.43, for a total transaction of $224,301.00.
- On Friday, October 30th, Jason Aryeh sold 1,411 shares of Ligand Pharmaceuticals stock. The shares were sold at an average price of $320.24, for a total value of $451,858.64.
Ligand Pharmaceuticals Trading Down 2.4%
Shares of NASDAQ:LGND traded down $7.48 during trading hours on Friday, hitting $308.79. 129,023 shares of the company’s stock traded hands, compared to its average volume of 215,877. Ligand Pharmaceuticals Incorporated has a 1 year low of $175.89 and a 1 year high of $326.63. The business has a fifty day moving average price of $301.71 and a 200-day moving average price of $258.02. The firm has a market capitalization of $6.18 billion, a P/E ratio of 137.85, a price-to-earnings-growth ratio of 5.52 and a beta of 1.16. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.22 and a quick ratio of 1.19.
Wall Street Analysts Forecast Growth
A number of research analysts have commented on LGND shares. Citigroup raised their target price on shares of Ligand Pharmaceuticals from $397.00 to $402.00 and gave the company a “buy” rating in a research report on Thursday, November 5th. Leerink Partners initiated coverage on shares of Ligand Pharmaceuticals in a research report on Friday, August 14th. They set an “outperform” rating and a $330.00 target price on the stock. Weiss Ratings downgraded Ligand Pharmaceuticals from a “buy (b)” rating to a “hold (c)” rating in a research report on Monday, November 2nd. Barclays increased their price objective on Ligand Pharmaceuticals from $345.00 to $350.00 and gave the company an “overweight” rating in a report on Wednesday. Finally, Oppenheimer restated an “outperform” rating and issued a $326.00 price objective (up from $285.00) on shares of Ligand Pharmaceuticals in a research note on Monday, August 3rd. Eight analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $355.38.
View Our Latest Stock Report on LGND
Institutional Trading of Ligand Pharmaceuticals
Institutional investors and hedge funds have recently made changes to their positions in the business. Marshall Wace LLP purchased a new stake in Ligand Pharmaceuticals in the 3rd quarter worth $9,904,000. AlphaGrep UK Ltd acquired a new position in shares of Ligand Pharmaceuticals during the 3rd quarter worth about $394,000. First Trust Advisors LP raised its position in shares of Ligand Pharmaceuticals by 30.3% during the 3rd quarter. First Trust Advisors LP now owns 118,399 shares of the biotechnology company’s stock worth $36,984,000 after purchasing an additional 27,506 shares during the last quarter. TIAA CREF Individual & Institutional Services LLC purchased a new position in Ligand Pharmaceuticals in the 3rd quarter valued at about $246,000. Finally, Advisors Asset Management Inc. purchased a new position in Ligand Pharmaceuticals in the 3rd quarter valued at about $10,584,000. 91.28% of the stock is currently owned by hedge funds and other institutional investors.
Ligand Pharmaceuticals Company Profile
Ligand Pharmaceuticals is a biopharmaceutical company that works with pharmaceutical and biotechnology partners to develop and commercialize medicines. Rather than focusing primarily on selling drugs directly, Ligand licenses technologies and drug-development assets and may receive royalties and other payments from partner programs. Its technologies include Captisol, a formulation platform designed to improve the solubility and delivery of certain medicines. Ligand also holds economic interests in a portfolio of partnered products and drug candidates across multiple therapeutic areas.
Recommended Stories
- Five stocks we like better than Ligand Pharmaceuticals
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
- Why Equinix and Digital Realty Benefit From Data Center Zoning Battles
Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
